Research progress of anti VEGF drugs in proliferative phase of diabetes retinopathy
糖尿病视网膜病变增殖期应用抗VEGF药物的研究进展

摘要

糖尿病眼底并发症中，糖尿病性视网膜病变（DR）的发病率最高。目前，对于增殖期糖尿病视网膜病变（PDR）的治疗方式主要有药物疗法、激光光凝疗法、糖皮质激素疗法、抗血管内皮生长因子（VEGF）疗法以及手术疗法。全视网膜光凝术被认为是DR患者视力恢复的首选方法，但由于激光的损害，可能引起一系列的副作用。相较于激光疗法，药物疗法可以在DR疾病的各个阶段提供干预，且还可以有效维持视网膜的解剖形态，从而降低激光引起的副作用。VEGF药物的作用是通过阻止VEGF的活性，从而阻止眼内新生血管的生成，与此同时，能够降低血管的透明度和减少血液的渗出，这也是当前PDR发展延迟的研究焦点。本篇文章将对VEGF药物在增殖期糖尿病视网膜病变的使用情况进行概述，通过对近几年的研究以及文献报告进行整理，为糖尿病性视网膜病变的治疗方法提供新思路。

Abstract

Among diabetic fundus complications, diabetic retinopathy (DR) has the highest incidence. At present, the main treatment methods for proliferative diabetic retinopathy (PDR) include drug therapy, laser photocoagulation therapy, glucocorticoid therapy, anti-vascular endothelial growth factor (VEGF) therapy and surgical therapy. Panretinal photocoagulation is considered as the preferred method for vision restoration in DR Patients, but it may cause a series of side effects due to laser damage. Compared to laser therapy, drug therapy can provide intervention at all stages of DR Disease, and can also effectively maintain the anatomical shape of the retina, thus reducing the side effects caused by laser. VEGF drugs work by blocking the activity of VEGF, thereby preventing the formation of new blood vessels in the eye, and at the same time, can reduce the transparency of blood vessels and reduce blood leakage, which is the focus of current research on the delayed development of PDR. In this paper, the use of VEGF in proliferative diabetic retinopathy will be summarized, and through the review of recent studies and literature reports, new ideas for the treatment of diabetic retinopathy will be provided.